Clinical Trials
26 trialsNeoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
Shanghai Pulmonary Hospital, Shanghai, China
Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer
University of Illinois at Chicago
Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
Universitas Airlangga
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NoCUT-BC
Ohio State University Comprehensive Cancer Center
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial
Sun Yat-sen University
ZBR in WM
Institute of Hematology & Blood Diseases Hospital, China
CISN-L
First Affiliated Hospital of Wenzhou Medical University
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
Changhai Hospital
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
TitAN
Qilu Hospital of Shandong University
Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer
Assiut University
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
Fudan University
Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC
RenJi Hospital
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
PEACE
Azienda Unita Sanitaria Locale di Piacenza
A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer
Xijing Hospital
Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC
Capital Medical University
Aromatherapy in the Treatment of Early Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Assiut University
Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer
St. James's Hospital, Ireland
Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer
ChineseAMS
Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer
The Catholic University of Korea
FOCUS
Shanghai Gynecologic Oncology Group